$0.9424
-0.0276-2.85%
最終更新: Oct 23, 1:58 PM
Benzinga
Benzinga
Benzinga
金曜日, 10 23
Benzinga
© 2026 Benzinga | All Rights Reserved
Cadrenal Therapeutics (CVKD) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.99 | $-1.56 | $-1.19 | $-1.72 |
| Actual | $-1.14 | $-1.04 | $-1.41 | $-1.31 |
| Surprise | -15.2% | +33.3% | -18.5% | +23.8% |
| Revenue | ||||
| Estimate | — | — | — | — |
| Actual | $0 | $0 | $0 | — |
| Surprise | — | — | — | — |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-0.93 | $-0.88 | $-0.88 | $-0.90 |
| Revenue | ||||
| Consensus | — | — | — | — |
| 会計四半期 | 報告日 | 実質EPS | 推定EPS | 驚き ％ |
|---|---|---|---|---|
| Q2 | Aug 13, 2026 | $-1.14 | $-0.99 | -15.2 % |
| Q1 | May 7, 2026 | $-1.04 | $-1.56 | 33.3 % |
| Q4 | Mar 31, 2026 | $-1.41 | $-1.19 | -18.5 % |
| Q3 | Nov 10, 2025 | $-1.31 | $-1.72 | 23.8 % |